Mucoadhesive carrier for delivery of therapeutical agent
First Claim
1. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being dehydroepiandrosterone, said polymer being polyethylene glycol having a number average molecular weight of about 4,000, and the weight ratio of dehydroepiandrosterone to said polyethylene glycol being about 1;
4, respectively.
1 Assignment
0 Petitions
Accused Products
Abstract
A mucoadhesive carried suitable for a therapeutic agent is disclosed. This carrier allows controlled release of the therapeutic agent via mucosal tissue. The mucoadhesive carrier comprises a Monolithic polymer matrix that is anhydrous but hydratable, and amorphous fumed silica. The silica enhances the mucoadhesive properties of the carrier. An optional water-insoluble barrier film or layer can be secured to the polymer matrix to provide a non-adhering face.
229 Citations
11 Claims
-
1. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being dehydroepiandrosterone, said polymer being polyethylene glycol having a number average molecular weight of about 4,000, and the weight ratio of dehydroepiandrosterone to said polyethylene glycol being about 1;
4, respectively. - View Dependent Claims (8, 9, 10, 11)
- said therapeutic agent being dehydroepiandrosterone, said polymer being polyethylene glycol having a number average molecular weight of about 4,000, and the weight ratio of dehydroepiandrosterone to said polyethylene glycol being about 1;
-
2. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being nifedipine, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of nifedipine to said polyethylene glycol being about 1;
2, respectively.
- said therapeutic agent being nifedipine, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of nifedipine to said polyethylene glycol being about 1;
-
3. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being piroxicam, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of piroxicam to said polyethylene glycol being about 1;
2, respectively.
- said therapeutic agent being piroxicam, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of piroxicam to said polyethylene glycol being about 1;
-
4. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being albuterol, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of albuterol to said polyethylene glycol being about 1;
2, respectively.
- said therapeutic agent being albuterol, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of albuterol to said polyethylene glycol being about 1;
-
5. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being dehydroepiandrosterone, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of dehydroepiandrosterone to said polyethylene glycol being about 1;
2, respectively.
- said therapeutic agent being dehydroepiandrosterone, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of dehydroepiandrosterone to said polyethylene glycol being about 1;
-
6. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being phenylpropanolamine, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of phenylpropanolamine to said polyethylene glycol being about 1;
2, respectively.
- said therapeutic agent being phenylpropanolamine, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of phenylpropanolamine to said polyethylene glycol being about 1;
-
7. A therapeutic dosage form comprising an anhydrous but hydratable monolithic polymer matrix that contains amorphous fumed silica as well as a therapeutic agent and defines a mucoadhesive face, and a water-insoluble barrier layer secured to said polymer matrix and defining a non-adhesive face;
- said therapeutic agent being 17 β
-estradiol, said polymer being polyethylene glycol having a number average molecular weight of about 8,000, and the weight ratio of 17 β
-estradiol to said polyethylene glycol being about 1;
2, respectively.
- said therapeutic agent being 17 β
Specification